Executive Order For Psychedelics

A conversation with Joseph Tucker, Ph.D., CEO, Enveric Biosciences

The White House recently issued an executive order accelerating the use of psychedelics, such as psilocybin, MDMA, and ibogaine, in research and clinical trials. This order, however, does not change the current legal status of any of them.

In this Q&A, Life Science Connect’s Morgan Kohler caught up with Joseph Tucker, Ph.D., CEO of Enveric Biosciences, to discuss the implications of this order and what it means for the industry.

What is your interpretation of the recent executive action on psychedelics in the context of the FDA’s existing accelerated pathways?

I view this as a strong directional signal rather than a fundamental regulatory change. The FDA already has tools like Fast Track and Breakthrough Therapy to help expedite and de-risk development programs. This new executive order is a strong signal, resonating across the federal government, saying “prioritize this field.” It probably means we can expect less bureaucratic foot dragging or lack of focus than might otherwise have been encountered.

How would you best summarize what this executive order states? What benefits and challenges for biotechs do you foresee arising as a result? What is the most important/meaningful thing you’d like biotechs to know in relation to this order?

In short, the executive order directs federal agencies to support and accelerate the research, development, regulatory review, and commercialization of psychedelic and psychedelic-inspired therapies for serious mental health conditions. It specifically calls out improving coordination between agencies, expanding use of FDA expedited pathways, supporting clinical research, and improving treatment access for conditions like PTSD, depression, and addiction.

In my opinion, the biggest impact may actually be at the earlier preclinical stage, not just in later-stage clinical programs. I think companies are going to find it easier to raise capital around serious preclinical neuropsychiatric programs, easier to engage regulators earlier, and easier to justify investment into translational science that previously may have been viewed as too speculative or niche.

At the same time, I do not think the scientific bar is being lowered at all. If anything, I think the heat is being turned up. More capital will come in and there will be more scrutiny on the underlying science. In my view, the companies that benefit most will be the ones that can answer the difficult mechanistic and translational questions early, before they become expensive clinical problems later on.

From a development standpoint, where do you expect to see the earliest tangible impact?

The broadest impact, in my opinion, will affect IND preparation and early clinical trials. Getting aligned with the FDA before entering the clinic can be challenging in fields of historical concern, like psychedelics, and with the top-down mandated prioritization of this space, companies developing such therapeutics will hopefully get clearer guidance and quicker responses during that process. That increased clarity can help early-stage companies with designing clinical trials that align with what regulators are looking for, further de-risking the program. There also will be a meaningful impact for a more narrowly defined group, those sponsors of late-stage assets that receive the Commissioner’s National Priority Voucher (CNPV). CNPVs could accelerate the review of the drug in question, from maybe six to 10 months down to one or two. That’s meaningful in the context of the market. However, the drug is still going to have to pass muster in terms of clinical benefit and safety.

How might expanded fast-track or accelerated pathways realistically influence IND timelines, trial design, and regulatory interactions for neuropsychiatric therapies?

Pathways like that don’t eliminate steps but they can reduce overall timelines, often thanks to tighter communication turnaround with the FDA. One might also be able to run smaller, more focused trials or get earlier efficacy signals. An important point I want to reiterate is that the clinical benefit bar is not being lowered, but the timeline in which you find out how the FDA feels about your efficacy and safety profile is getting compressed. It will be quicker to achieve your result, whichever it is, good or bad.

How are regulators currently thinking about risk-benefit profiles in this category, particularly around safety, tolerability, and functional impairment?

There are many serious but undertreated mental health conditions that this executive order is calling out as needing to be addressed with greater alacrity and priority. Regulators are often willing to accept some short-term side effects for urgent situations, in particular if they are manageable and happen in controlled settings.

With hallucinogenic psychedelics, however, you have to be extra cautious because the scientific literature tells us there is a non-zero potential for lasting cognitive or functional problems. Next-generation non-hallucinogenic approaches aim to deliver such benefits to patients without disrupting normal function, so the acceleration of the psychedelic field overall may ultimately resolve into being the acceleration of the switchover to next-generation non-hallucinogenic approaches, away from the classical hallucinogenic approaches.

Are you seeing a shift in what investors prioritize?

Investors in the psychedelics field have historically, in my opinion, been focused on time to market. This latest move though, and at least so far the market seems to be bearing this out, appears to be a shift in appetite to narratives that focus on safety and scalability. The earlier-stage companies seem to have benefited, in the stock market, to a greater relative proportion than the companies advancing later-stage assets. There is not at present, in my opinion, an obviously strong desire for platform stories if they don’t also easily communicate a clear and rapidly scalable commercialization path. Time to market still holds a lot of impact, so long as the path is credible. Meanwhile, investors are starting to consider, “can this treatment actually reach large patient populations, or is it going to be constrained by infrastructure requirements in its growth trajectory?”

Even with accelerated pathways, what will ultimately determine whether these therapies reach broad clinical adoption?

Adoption will come down to how accessible and easy these therapies are to use. Treatments that require complex monitoring or specialized clinics will face patient access, and thus market growth, constraints. Broadly speaking, one can expect that doctors and payers will prefer options that fit into existing care settings. Durability of a treatment’s effects is also an important factor to consider, since this impacts patient outcomes and cost-effectiveness. Eventually, the therapies that end up dominating the market will probably be those developed by companies that have figured out how to combine strong, durable benefit with simple, scalable delivery.

If you had to separate signal from noise right now, what should industry stakeholders be paying the most attention to over the next 12 to 24 months?

The most important signal of strong, durable benefit will come from clinical results that clearly show the drug itself is driving the benefit. The question of the unblinding of patients and clinicians affecting the clinical trial results has not yet been fully resolved, in my opinion. Differentiation between therapeutics around safety profile and accessibility or scalability is also going to start to be very meaningful.

Having said that, I think the biggest thing to watch over the next 12 to 24 months is which companies can turn interesting preclinical ideas into real translational evidence. There is going to be a lot of noise around the word “psychedelic,” but the signal will be in the data, specifically regarding mechanism of action, receptor selectivity, safety, and whether the approach can plausibly become a scalable medicine.

I think stakeholders should pay close attention to companies that have plausible answers to the hard questions. Can they separate therapeutic benefit from hallucination or functional impairment? Can they explain why their molecule should work in a specific disease? Can the product fit into normal medical practice, or does it require a complex treatment infrastructure?

To me, that is where the field is going. The next phase will not be won by companies with the loudest psychedelic narrative. It will be won by companies that can show a practical path to becoming real pharmaceutical products.

About The Expert

Joseph Tucker, Ph.D., is a seasoned executive who has built several publicly traded biotechnology companies. He was a founder and CEO of Stem Cell Therapeutics. Trillium Therapeutics acquired Stem Cell Therapeutics in 2013. Tucker has also held the position of coFounder and CEO of Epimeron Inc., a University of Calgary start-up acquired in the creation of Willow Biosciences Inc. At Willow, he served as executive chairman and COO. Prior to founding companies, Tucker was a healthcare analyst with two investment banks and has also worked in technology commercialization for a university technology transfer office. He received his Ph.D. in biochemistry and molecular biology from the University of Calgary.